ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323000036 |
| _version_ | 1828004404194705408 |
|---|---|
| author | Huihui Li, BM Tianqi Song, BM Xiaoling Xu, MD |
| author_facet | Huihui Li, BM Tianqi Song, BM Xiaoling Xu, MD |
| author_sort | Huihui Li, BM |
| collection | DOAJ |
| description | SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment. |
| first_indexed | 2024-04-10T07:13:08Z |
| format | Article |
| id | doaj.art-9b4837b2eea84ec5932afd77664ac016 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-10T07:13:08Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-9b4837b2eea84ec5932afd77664ac0162023-02-26T04:28:21ZengElsevierJTO Clinical and Research Reports2666-36432023-02-0142100464ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case ReportHuihui Li, BM0Tianqi Song, BM1Xiaoling Xu, MD2The Second Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, People’s Republic of ChinaThe Second Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, People’s Republic of ChinaThe Second Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, People’s Republic of China; Corresponding author. Address for correspondence: Xiaoling Xu, MD, Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, People’s Republic of China.SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment.http://www.sciencedirect.com/science/article/pii/S2666364323000036Anasplastic lymphoma kinaseLung adenocarcinomaLorlatinibResistanceSmall cell lung cancerCase report |
| spellingShingle | Huihui Li, BM Tianqi Song, BM Xiaoling Xu, MD ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report JTO Clinical and Research Reports Anasplastic lymphoma kinase Lung adenocarcinoma Lorlatinib Resistance Small cell lung cancer Case report |
| title | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
| title_full | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
| title_fullStr | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
| title_full_unstemmed | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
| title_short | ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report |
| title_sort | alk positive adenocarcinoma after acquired resistance to lorlatinib and transformation to sclc a case report |
| topic | Anasplastic lymphoma kinase Lung adenocarcinoma Lorlatinib Resistance Small cell lung cancer Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323000036 |
| work_keys_str_mv | AT huihuilibm alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport AT tianqisongbm alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport AT xiaolingxumd alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport |